Excise duty framework for cannabis products
https://policybase.cma.ca/link/policy13799

POLICY TYPE  Response to consultation
DATE        2017-12-07
TOPICS      Pharmaceuticals, prescribing, cannabis, drugs

Documents
Non-prescription availability of low-dose codeine products

https://policybase.cma.ca/link/policy13734

POLICY TYPE
Response to consultation

DATE
2017-11-7

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission:
Non-Prescription Availability of Low-Dose Codeine Products

Submission to the Health Canada consultation on the potential risks, benefits and impacts of changes to the regulations to the Controlled Drugs and Substances Act that would require all products containing codeine to be sold by prescriber only.

November 7, 2017
Bill C−45: The Cannabis Act
https://policybase.cma.ca/link/policy13723

POLICY TYPE
Parliamentary submission

DATE
2017-08-18

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA response to patented medicines regulations consultations
https://policybase.cma.ca/link/policy13690

POLICY TYPE  Response to consultation
DATE          2017-06-28
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents

Canada’s lower-risk cannabis use guidelines (LRCUG)
https://policybase.cma.ca/link/policy13726

POLICY TYPE  Policy endorsement
DATE          2017-05-26
TOPICS        Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA’s Recommendations for Bill S–5: An Act to amend the Tobacco Act and the Non-smokers’ Health Act and to make consequential amendments to other Acts
https://policybase.cma.ca/link/policy13641

POLICY TYPE  Parliamentary submission
DATE  2017-04-07
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents
CMA submission to the study of Bill C-37
https://policybase.cma.ca/link/policy13617

POLICY TYPE
Parliamentary submission

DATE
2017-04-06

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CMA Submission to the study of Bill C-37
An Act to amend the Controlled Drugs and Substances Act and to make related amendments to other Acts

Submission to the Senate Standing Committee on Legal and Constitutional Affairs

April 6, 2017
Consultation on the renewal of Federal Tobacco Control Strategy
https://policybase.cma.ca/link/policy13804

POLICY TYPE  Response to consultation
DATE  2017-04-05
TOPICS  Health care and patient safety
Pharmaceuticals, prescribing, cannabis, drugs

Documents

April 5, 2017

Chair of the Federal Tobacco Control Strategy

Dear [Name],

We are writing in response to your letter regarding the renewal of the Federal Tobacco Control Strategy (FTCS) and the consultation on its renewal.

The 2017 Canadian Tobacco Use Survey (CTUS) reports that 27% of the population smoked in 2016. We welcome the government's decision to listen to experts and to take action to reduce the burden of smoking-related diseases. Tobacco control is an urgent public health priority, and we welcome the government's decision to take action.

The CMA supports the government's efforts to reduce tobacco use and the associated health burden. We are committed to working with the government to achieve these goals.

Sincerely,

[Name]
Canadian Medical Association